ChemicalBook > CAS DataBase List > Aducanumab

Aducanumab

Product Name
Aducanumab
CAS No.
1384260-65-4
Chemical Name
Aducanumab
Synonyms
BIIB037;Aducanumab;Aducanumab (anti-APP);Research Grade Aducanumab;Research Grade Aducanumab(DHC12504);AducanumabQ: What is Aducanumab Q: What is the CAS Number of Aducanumab
CBNumber
CB63143751
Formula Weight
0
MOL File
Mol file
More
Less

Aducanumab Property

storage temp. 
Store at -80°C, Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws
form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Aducanumab Chemical Properties,Usage,Production

History

Aducanumab(brand name Aduhelm) was discovered by Biogen and Eisai, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque)[3][4] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. Granted accelerated approval by the United States Food and Drug Administration (FDA) in June 2021, aducanumab is the first AD treatment to receive formal regulatory clearance since 2003.

Uses

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research[1].

Enzyme inhibitor

This high-affinity, fully human IgG1 monoclonal antibody (MW = 149.5 kDa; CAS 1384260-65-4), also known by the developmental code name BIIB037, selectively targets aggregated forms of b-amyloid protein (EC50 = 0.1 nM), while showing weak binding to Ab monomer. In the brains of transgenic mice, aducanumab preferentially binds to parenchymal Aβ over vascular Aβ deposits, consistent with the lack of effect on vascular Aβ following chronic dosing. Aducanumab dose-dependently reduces amyloid deposition in six cortical regions of the brain. chAducanumab, a murine IgG2a/κ chimeric analogue, dose-dependently reduces Aβ measured in brain homogenates by up to 50% relative to the vehicle control in the diethylamine fraction that extracted soluble monomeric and oligomeric forms of Aβ40 and Aβ42, and in the guanidine hydrochloride fraction that extracted insoluble Aβ fibrils. The clearance of Aβ deposits was accompanied by enhanced recruitment of microglia. Together with the reduced potency of the aglycosylated form of chaducanumab and the ex vivo phagocytosis data, such findings suggest that FcγR-mediated microglial recruitment and phagocytosis played an important role in Aβ clearance in these models. Activated microglia appeared to encapsulate the remaining central dense core of plaques in treated animals, possibly isolating them from the surrounding neurophil.

in vivo

Aducanumab (30 mg/kg, i.p., single dose) binds all morphological types of brain Aβ plaques in 22-month-old Tg2576 transgenic mice, including diffuse Aβ deposits and compact Aβ plaques[1].
Aducanumab (0.3-30 mg/kg, i.p., weekly, 6 months) reduces soluble and insoluble Aβ in a dose-dependent manner in 9.5- to 15.5-month-old Tg2576 transgenic mice[1].
Aducanumab (10 mg/kg, i.p., weekly, 6 months) restores intracellular calcium to control levels in 18-month-old Tg2576 mice[2].
Aducanumab (0.4-1 mg/mL, ICV, 20 min) leads to rapid decrease in amyloid burden, plaque clearance in Tg2576 mice[2].

Animal Model:9.5- to 15.5-month-old Tg2576 transgenic mice [1]
Dosage:0.3-30 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques.
Animal Model:18-month-old Tg2576 mice[2]
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result:Restored neurite baseline calcium to control levels.
Decreased the number of neurites with elevated levels of calcium after 2 weeks.
Decreased the percentage of cell bodies with calcium overload.
Restored the levels of VILIP and SERCA to control levels.
Increased the cell numbers of NR1 and NR2A.
Animal Model:22-month-old transgenic Tg2576 mice[2]
Dosage:0.4-1 mg/mL
Administration:Intracerebroventricular injection (ICV), 20 min
Result:Decreased the number of amyloid plaque.
Decreased the size of the remaining individual plaques.
Reduced amyloid plaque burden.

References

[1] Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6. DOI:10.1038/nature19323
[2] Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36(50):12549-12558. DOI:10.1523/JNEUROSCI.2080-16.2016

Aducanumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Aducanumab Suppliers

Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Fax
+86 (27) 8331-4682
Email
whsrtech@vip.163.com
Country
China
ProdList
246
Advantage
62
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Nanjing Peptide Biotech Ltd.
Tel
025-58361106-805 15951641583
Fax
025-58361106-806
Email
zhao.xu@njpeptide.com
Country
China
ProdList
9979
Advantage
55
Hefei Hirisun Pharmatech Co., Ltd.
Tel
+86-0551-62678551 +86-15056975894
Fax
05512678551
Email
sales@hirisunpharm.com
Country
China
ProdList
176
Advantage
55
Nanjing Meihao Pharmaceutical Technology Co., Ltd.
Tel
meitaochem@126.com
Email
meitaochem@126.com
Country
China
ProdList
19103
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Jiangsu Greature Bio-Medicine Co., Ltd.
Tel
0512-85557988 18662338937
Fax
0512-85557182
Email
frank.wang@greature.com.cn
Country
China
ProdList
147
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Shanghai Minkai Biological Technology Co., Ltd
Tel
021-021-52919136 17315815539
Email
2804155403@qq.com
Country
China
ProdList
180
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824 18107960669
Fax
18140514863
Email
79046690@qq.com
Country
China
ProdList
1242
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
59936
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
185-0276-2003 18502762003;
Email
435918333@qq.com
Country
China
ProdList
2213
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Nantong QuanYi Biotechnology Co., Ltd
Tel
0513-66337626 18051384581
Email
sales@chemhifuture.com
Country
China
ProdList
5929
Advantage
58
Wuhan Acumen Bio-Technology Co.,ltd
Tel
027-027-16602739303 16602739303
Email
673003916@qq.com
Country
China
ProdList
2935
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509; 17721492509
Email
643638326@qq.com
Country
China
ProdList
4970
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Email
2853877583@QQ.com
Country
China
ProdList
7499
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59101766 13125137661
Email
2853877621@qq.com
Country
China
ProdList
7979
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9765
Advantage
58
Wanxin Biotechnology (Jiaxing) Co., LTD
Tel
0573-83568680 18057391398
Email
3956524501@qq.com
Country
China
ProdList
1442
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
Chengdu Peter-like Biotechnology Co., Ltd.
Tel
028-81700200 13308200041
Email
2851167782@qq.com
Country
China
ProdList
11146
Advantage
58
Sangon Biotech (Shanghai) Co.,Ltd.
Tel
400-821-026
Email
Sales@sangon.com
Country
China
ProdList
6710
Advantage
58
AntibodySystem Laboratories SAS
Tel
33175446423
Email
support@antibodysystem.com
Country
China
ProdList
6739
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Cell Sciences
Tel
9785721070
Email
info@cellsciences.com
Country
China
ProdList
6308
Advantage
58
Suzhou Genelee Bio-Technology Co., Ltd
Tel
86-17715515539 17715515539
Email
James@geneleebio.com
Country
China
ProdList
41
Advantage
58
Henan Tianfu Chemical Co.,Ltd.
Tel
+86-0371-55170693 +86-19937530512
Fax
0371-55170693
Email
info@tianfuchem.com
Country
China
ProdList
21612
Advantage
55
Zibo Hangyu Biotechnology Development Co., Ltd
Tel
+86-0533-2185556 +8615965530500
Email
nickzhang@hangyubiotech.com
Country
China
ProdList
8510
Advantage
58
Guangzhou Zhuanyan Biotechnology Co., Ltd.
Tel
18926165828
Country
CHINA
ProdList
198
Advantage
58
Guangzhou Suyan Biotechnology Co., Ltd
Tel
18818417021
Country
CHINA
ProdList
127
Advantage
58
Shanghai Yemeng Biotechnology Co., Ltd
Tel
13764917104
Country
CHINA
ProdList
142
Advantage
58
Proteintech China
Tel
--
Fax
--
Email
Proteintech-CN@ptglab.com
Country
CHINA
ProdList
6290
Advantage
58

1384260-65-4, AducanumabRelated Search:


  • Aducanumab
  • AducanumabQ: What is Aducanumab Q: What is the CAS Number of Aducanumab
  • Research Grade Aducanumab(DHC12504)
  • Aducanumab (anti-APP)
  • BIIB037
  • Research Grade Aducanumab
  • 1384260-65-4